METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial–mesenchymal transition
Journal of Molecular Cell Biology · 03.08.2023 · 15 (3)
DOI: 10.1093/jmcb/mjad005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Cell Biology, online erschienen am 21.03.2023. Verfasst von Yuwei Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Methyltransferases. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Technologies R&D Program, Shanghai Hospital Development Center.
Abstract (Originalsprache)
Subretinal fibrosis is a major cause of the poor visual prognosis for patients with neovascular age-related macular degeneration (nAMD). Myofibroblasts originated from retinal pigment epithelial (RPE) cells through epithelial–mesenchymal transition (EMT) contribute to the fibrosis formation. N6-Methyladenosine (m6A) modification has been implicated in the EMT process and multiple fibrotic diseases. The role of m6A modification in EMT-related subretinal fibrosis has not yet been elucidated. In this study, we found that during subretinal fibrosis in the mouse model of laser-induced choroidal neovascularization, METTL3 was upregulated in RPE cells. Through m6A epitranscriptomic microarray and further verification, high-mobility group AT-hook 2 (HMGA2) was identified as the key downstream target of METTL3, subsequently activating potent EMT-inducing transcription factor SNAIL. Finally, by subretinal injections of adeno-associated virus vectors, we confirmed that METTL3 deficiency in RPE cells could efficiently attenuate subretinal fibrosis in vivo. In conclusion, our present research identified an epigenetic mechanism of METTL3–m6A–HMGA2 in subretinal fibrosis and EMT of RPE cells, providing a novel therapeutic target for subretinal fibrosis secondary to nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
- Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai 200080, China.
- Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, China.
- National Clinical Research Center for Eye Diseases, Shanghai 200080, China.
- Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China.
Förderung
- National Natural Science Foundation of China
- National Key Technologies R&D Program
- Shanghai Hospital Development Center
Zitieren
APA
Wang, Y., Chen, Y., Liang, J., Jiang, M., Zhang, T., Wan, X., Wu, J., Li, X., Chen, J., Sun, J., Hu, Y., Huang, P., Feng, J., Liu, T., & Sun, X. (2023). METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial–mesenchymal transition. Journal of Molecular Cell Biology, 15(3). https://doi.org/10.1093/jmcb/mjad005
Vancouver
Wang Y, Chen Y, Liang J, Jiang M, Zhang T, Wan X, et al. METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial–mesenchymal transition. Journal of Molecular Cell Biology. 2023;15(3). doi:10.1093/jmcb/mjad005
BibTeX
@article{Wang2023,
author = {Wang, Yuwei and Chen, Yuhong and Liang, Jian and Jiang, Mei and Zhang, Ting and Wan, Xiaoling and Wu, Jiahui and Li, Xiaomeng and Chen, Jieqiong and Sun, Junran and Hu, Yifan and Huang, Peirong and Feng, Jingyang and Liu, Te and Sun, Xiaodong},
title = {METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial–mesenchymal transition},
journal = {Journal of Molecular Cell Biology},
year = {2023},
volume = {15},
number = {3},
doi = {10.1093/jmcb/mjad005}
}
EUVIMED